Sugi Predict

Sugi Predict / Compounds / SCHEMBL9860948

SCHEMBL9860948

SCHEMBL9860948

Cc1c(Br)cccc1CCl

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GABRA1 P14867 2/20 0.39
▸ GABRB2 P47870 2/20 0.39
▸ TSHR P16473 3/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.37
▸ LMNA P02545 2/20 0.37
▸ BLM P54132 1/20 0.37
▸ TAAR1 Q96RJ0 3/20 0.36
▸ IDO1 P14902 2/20 0.34
▸ PYCR1 P32322 1/20 0.32
▸ PDCD1 Q15116 1/20 0.31
▸ CD274 Q9NZQ7 1/20 0.31
▸ DHFR P00374 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6914998 0.83 TSHR (0.38) GABRA1GABRB2TSHRHSD17B10ALDH1A1
SCHEMBL28526601 0.79 TSHR (0.38) GABRA1GABRB2TSHRCYP1A2CYP2D6
SCHEMBL149686 0.79 GABRA1 (0.41) GABRA1GABRB2TSHRCYP1A2CYP2D6
SCHEMBL7322742 0.79 GABRA1 (0.58) GABRA1GABRB2TSHRCYP1A2CYP2D6
SCHEMBL30267045 0.79 GABRA1 (0.41) GABRA1GABRB2TSHRCYP1A2CYP2D6
SCHEMBL31142838 0.77 TAAR1 (0.45) GABRA1GABRB2TSHRALDH1A1TAAR1
SCHEMBL608459 0.77 TAAR1 (0.45) GABRA1GABRB2TSHRALDH1A1TAAR1
SCHEMBL21928918 0.77 GABRA1 (0.39) GABRA1GABRB2TSHRCYP1A2CYP2D6
SCHEMBL147988 0.77 PDCD1 (0.53) GABRA1GABRB2TSHRALDH1A1TAAR1
SCHEMBL5482813 0.77 GABRA1 (0.35) GABRA1GABRB2TSHRCYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118307540-B Synthesis method of avibactam sodium 浙江尖峰药业有限公司 2024-10-15 — — CN claimed
CN-118307540-A Synthesis method of avibactam sodium 浙江尖峰药业有限公司 2024-07-09 — — CN claimed
US-12590062-B2 PD-1/PD-L1 inhibitors GILEAD SCIENCES, INC. (US) 2026-03-31 — — US disclosed
US-20250223286-A1 IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF BETTA PHARMACEUTICALS CO.,LTD (CN) 2025-07-10 — — US disclosed
US-12187713-B2 Immunomodulators, compositions and methods thereof BETTA PHARMACEUTICALS CO., LTD (CN) 2025-01-07 — — US disclosed
CN-118307540-B Synthesis method of avibactam sodium 浙江尖峰药业有限公司 2024-10-15 — — CN disclosed
CN-116730940-B Heterocyclic substituted biphenyl compound and medical application thereof 中国药科大学 2024-08-30 — — CN disclosed
CN-118307540-A Synthesis method of avibactam sodium 浙江尖峰药业有限公司 2024-07-09 — — CN disclosed
CN-117964559-A 8-Phenylquinazoline compound and application thereof 华侨大学 2024-05-03 — — CN disclosed
CN-115368277-B Biphenyl compound containing hydroxamic acid structure and application thereof 华侨大学 2024-03-29 — — CN disclosed
CN-110536885-B Process for producing difluoromethylene compound 佐藤制药株式会社 2024-03-08 — — CN disclosed
CN-105705509-A 4-{4-[(1 e)-4-(2,9-diazaspiro[5.5]undec-2-yl)but-1 -en-1 -yl]-2-methylbenzyl}-5-(propan-2-yl)-1 h-pyrazol-3-yl beta-d- glucopyranoside acetate 伊莱利利公司 2016-06-22 — — CN disclosed
US-20150191463-A1 DIFLUOROMETHYLENE COMPOUND SATO PHARMACEUTICAL CO., LTD. (JP) 2015-07-09 — — US disclosed
US-20150191463-A1 DIFLUOROMETHYLENE COMPOUND SATO PHARMACEUTICAL CO., LTD. (JP) 2015-07-09 — — US disclosed
US-20150191463-A1 DIFLUOROMETHYLENE COMPOUND SATO PHARMACEUTICAL CO., LTD. (JP) 2015-07-09 — — US disclosed
EP-2878594-A1 DIFLUOROMETHYLENE COMPOUND Sato Pharmaceutical Co., Ltd. (JP) 2015-06-03 — — EP disclosed
EP-2878594-A1 DIFLUOROMETHYLENE COMPOUND Sato Pharmaceutical Co., Ltd. (JP) 2015-06-03 — — EP disclosed
US-4990716-A Preparation of diphenylmethanes THE DOW CHEMICAL COMPANY (US) 1991-02-05 — — US disclosed
US-4117019-A MANUFACTURE OF O-BENZYLTOLUENES BASF AKTIENGESELLSCHAFT (DE) 1978-09-26 — — US disclosed
US-3978144-A MANUFACTURE OF O-BENZYLTOLUENES BASF AKTIENGESELLSCHAFT (DT) 1976-08-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250223286-A1 IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF IL2, IL5, TSLP GABRA1 2116/4885GABRB2 2007/4885TSHR 3037/4885
US-12590062-B2 PD-1/PD-L1 inhibitors CD274, PDCD1LG2, PDCD1 GABRA1 192/4885GABRB2 238/4885TSHR 54/4885
US-12187713-B2 Immunomodulators, compositions and methods thereof IL2, TSLP, CD74 GABRA1 2026/4885GABRB2 1840/4885TSHR 3149/4885
US-20150191463-A1 DIFLUOROMETHYLENE COMPOUND XDH, SULT1A1, RFT1 GABRA1 3730/4885GABRB2 3649/4885TSHR 2749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.